The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
CREDIT DESIGNATION STATEMENT
The AACR has designated this live activity for a maximum of 27.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
CLAIMING (CME) CREDIT
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the CME Request for Credit Survey, below, by Wednesday, December 4, 2013. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you by email after the completion of the activity.
STATEMENT OF EDUCATIONAL NEED, TARGET AUDIENCE AND LEARNING OBJECTIVES
Molecularly targeted therapies have achieved great success from the “early days” of selective estrogen receptor modulators and aromatase inhibitors to more recent developments in signal transduction, histone deacetylases and proteasome inhibitors. However, for each of these success stories, there are new challenges in terms of resistance, further refinement of these “targeted therapies” based on molecular sub-classification, and the opportunity to develop new combination therapies.
Targeted cancer therapeutics allow practicing clinicians to tailor cancer treatment, especially when a target is present in some but not all tumors of a particular type. Eventually, treatments may be individualized based on the unique set of molecular targets produced by the patient’s tumor. Targeted cancer therapies also hold the promise of being more selective for cancer cells than normal cells, thus harming fewer normal cells, reducing side effects and improving quality of life.
Attendees at this program will be exposed to the latest research in the areas of overcoming resistance; immunotherapy; new combination therapies and novel models; and new approaches to target apoptotic and epigenetic regulators, cell cycle, DNA repair, metabolism, and KRAS mutant cancers. Discussions from the podium, during the poster sessions, and the informal interactions throughout the conference will spur new collaborations and provide guidance on future treatment opportunities for patients.
After participating in this CME activity, physicians should be able to:
- Identify epigenetic and apoptotic regulators being developed for targeted therapies;
- Compare new molecular diagnostic technologies and non-invasive methods of monitoring cancer with existing “best practices;”
- Explain the use of genomic data for drug development and its implications for treatment response;
- Assess the state of immunotherapy and combination therapy and their potential impact for molecularly-targeted therapy; and
- Articulate the late advances in therapies targeting metabolism, KRAS, and cell cycle/DNA repair.
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.
ACKNOWLEDGEMENT OF FINANCIAL OR OTHER SUPPORT
This activity is supported by grants and will be disclosed at the activity.
QUESTIONS ABOUT CME?
Please contact the Office of CME at (215) 440-9300 or email@example.com.
*Adobe Acrobat Reader required